Clinical Trial Update: Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the chemotherapy combination of ifosfamide and doxorubicin in patients with refractory nasopharyngeal carcinoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Doxorubicin (doxorubicin)
• IFOSFAMIDE (IFOSFAMIDE)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Refractory Nasopharyngeal Carcinoma | Phase 2 | Status: TERMINATED